- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.90 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NBG: N-acetyl-beta-D-glucopyranosylamine(Non-covalent)
- 2 x PLP: PYRIDOXAL-5'-PHOSPHATE(Covalent)
PLP.2: 15 residues within 4Å:- Chain A: Y.92, G.136, G.137, W.493, V.569, K.570, K.576, Y.650, R.651, V.652, A.655, G.677, T.678, G.679, K.682
14 PLIP interactions:14 interactions with chain A- Hydrophobic interactions: A:Y.92, A:Y.650, A:V.652, A:K.682
- Hydrogen bonds: A:T.678, A:G.679
- Water bridges: A:G.137, A:K.570, A:K.570, A:K.576, A:K.576, A:N.680
- Salt bridges: A:K.570, A:K.576
PLP.7: 14 residues within 4Å:- Chain B: Y.92, G.136, G.137, W.493, K.570, K.576, Y.650, R.651, V.652, A.655, G.677, T.678, G.679, K.682
16 PLIP interactions:16 interactions with chain B- Hydrophobic interactions: B:Y.92, B:Y.650, B:V.652, B:K.682
- Hydrogen bonds: B:Y.650, B:T.678, B:T.678, B:G.679
- Water bridges: B:Y.92, B:G.137, B:K.570, B:K.570, B:K.576, B:N.680
- Salt bridges: B:K.570, B:K.576
- 2 x CFF: CAFFEINE(Non-covalent)
CFF.3: 6 residues within 4Å:- Chain A: N.284, F.287, H.573, A.612, G.614, Y.615
4 PLIP interactions:4 interactions with chain A- Water bridges: A:R.772
- pi-Stacking: A:F.287, A:F.287, A:Y.615
CFF.8: 6 residues within 4Å:- Chain B: N.284, F.287, H.573, A.612, G.614, Y.615
4 PLIP interactions:4 interactions with chain B- Water bridges: B:R.772
- pi-Stacking: B:F.287, B:F.287, B:Y.615
- 2 x 055: (2S)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid(Non-covalent)
055.4: 13 residues within 4Å:- Chain A: W.69, I.70, Q.73, Q.74, R.195, F.198, D.229, R.244, R.312
- Chain B: V.42, K.43, D.44, V.47
18 PLIP interactions:14 interactions with chain A, 4 interactions with chain B- Hydrophobic interactions: A:W.69, A:I.70, A:Q.73, A:Q.73, A:Q.74, A:Q.74, B:V.42, B:V.47
- Hydrogen bonds: A:Q.73, B:V.42, B:D.44
- Water bridges: A:R.83, A:R.312
- Salt bridges: A:R.83, A:R.312
- pi-Stacking: A:W.69, A:F.198
- pi-Cation interactions: A:R.195
055.11: 16 residues within 4Å:- Chain A: V.42, K.43, D.44, N.46, V.47
- Chain B: W.69, I.70, Q.73, Q.74, Y.77, R.195, F.198, D.229, R.244, R.311, R.312
22 PLIP interactions:5 interactions with chain A, 17 interactions with chain B- Hydrophobic interactions: A:V.42, A:V.47, A:V.47, B:W.69, B:I.70, B:Q.73, B:Q.73, B:Q.74, B:Q.74, B:Y.77, B:R.311
- Hydrogen bonds: A:V.42, A:D.44, B:Q.73, B:R.195
- Water bridges: B:R.83, B:R.83
- Salt bridges: B:R.83, B:R.312
- pi-Stacking: B:W.69, B:F.198
- pi-Cation interactions: B:R.195
- 2 x MPD: (4S)-2-METHYL-2,4-PENTANEDIOL(Non-functional Binders)
MPD.5: 3 residues within 4Å:- Chain A: H.203, W.217, R.353
1 PLIP interactions:1 interactions with chain A- Hydrogen bonds: A:R.353
MPD.12: 5 residues within 4Å:- Chain B: L.495, E.503, A.506, E.511, Y.513
4 PLIP interactions:4 interactions with chain B- Hydrophobic interactions: B:L.495, B:E.503
- Hydrogen bonds: B:E.511, B:E.511
- 2 x MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID(Non-covalent)
MES.9: 8 residues within 4Å:- Chain B: I.172, R.173, D.174, G.175, E.554, Y.555, T.626, E.648
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:G.175
- Water bridges: B:D.174
- Salt bridges: B:E.648
MES.10: 7 residues within 4Å:- Chain B: R.51, R.95, E.126, I.127, E.128, E.129, R.651
6 PLIP interactions:6 interactions with chain B- Hydrogen bonds: B:R.95, B:R.651
- Water bridges: B:R.51, B:D.130
- Salt bridges: B:R.51, B:E.129
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Thomson, S.A. et al., Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy. Bioorg.Med.Chem.Lett. (2009)
- Release Date
- 2009-01-27
- Peptides
- Glycogen phosphorylase, liver form: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.90 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NBG: N-acetyl-beta-D-glucopyranosylamine(Non-covalent)
- 2 x PLP: PYRIDOXAL-5'-PHOSPHATE(Covalent)
- 2 x CFF: CAFFEINE(Non-covalent)
- 2 x 055: (2S)-{[(3-{[(2-chloro-6-methylphenyl)carbamoyl]amino}naphthalen-2-yl)carbonyl]amino}(phenyl)ethanoic acid(Non-covalent)
- 2 x MPD: (4S)-2-METHYL-2,4-PENTANEDIOL(Non-functional Binders)
- 2 x MES: 2-(N-MORPHOLINO)-ETHANESULFONIC ACID(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Thomson, S.A. et al., Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy. Bioorg.Med.Chem.Lett. (2009)
- Release Date
- 2009-01-27
- Peptides
- Glycogen phosphorylase, liver form: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B